Kytopen Teams Up With Aldevron To Enhance Workflow Solutions For Cell Therapy Developers
(RTTNews) - Kytopen Corp., and Aldevron, a subsidiary of Danaher Corp. (DHR), Tuesday announced a collaboration to improve the workflow solutions for cell therapy manufacturers, expecting to save time in a cost-effective manner.
The partnership will focus on the joint promotion of the synergies achieved by combining the Aldveron Nanoplasmid vector technology with Kytopen's Flowfect Tx GMP cellular engineering platform in CRISPR-mediated engineering of primary T Cells.
Aldevron stated that the partnership would meet the growing patient demand, which has increased with the adoption of CRISPR-based therapies.
Currently, Danaher's stock is trading at $196.23, up 0.32 percent on the New York Stock Exchange.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.